VolitionRX Limited (VNRX) News

VolitionRX Limited (VNRX): $0.75

0.07 (+10.74%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

D

Filter VNRX News Items

VNRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VNRX News Highlights

  • VNRX's 30 day story count now stands at 3.
  • Over the past 19 days, the trend for VNRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.

Latest VNRX News From Around the Web

Below are the latest news stories about VOLITIONRX LTD that investors may wish to consider to help them evaluate VNRX as an investment opportunity.

Sidoti Events, LLC's Virtual December Small-Cap Conference

NEW YORK, NY / ACCESSWIRE / December 5, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day December Small-Cap Conference taking place Wednesday and Thursday, December ...

Yahoo | December 5, 2023

VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximately $5.5 million) in financing from Wallonie Entreprendre S.A. ("WE") in Belgium.

Yahoo | December 5, 2023

VolitionRx Limited (AMEX:VNRX) Q3 2023 Earnings Call Transcript

VolitionRx Limited (AMEX:VNRX) Q3 2023 Earnings Call Transcript November 15, 2023 Operator: Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited Third Quarter 2023 Earnings Conference Call. During today’s presentation, all parties will be in a listen-only mode. Following the presentation, the conference call will be opened for questions. [Operator […]

Yahoo | November 16, 2023

VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update

VolitionRx Limited (NYSE American: VNRX) ("Volition") today announced financial results and a business update for the third quarter ended September 30, 2023. Volition management will host a conference call tomorrow, November 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Yahoo | November 14, 2023

VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday, November 15 at 8.30 a.m. U.S. Eastern Time to discuss its financial and operating results for the third quarter 2023, in addition to providing a business update. Details of this event can also be found below.

Yahoo | November 8, 2023

Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality diagnostic laboratory, have joined forces to launch the Nu.Q® Vet Cancer Test to veterinary practices in the UK and Ireland.

Yahoo | November 6, 2023

VNRX: Breakthrough Cancer Detection Method Disclosed at ESMO and in a Webinar - preliminary proof of concept work indicates simple blood test should be able to detect several types of cancer, potentially at Stages I & II

By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT VolitionRx (NYSE:VNRX) announced a new breakthrough cancer detection method at ESMO 2023 (European Society for Medical Oncology), which was followed up by an informative webinar with an informative slide deck . Each is accessible through one of the following links: Webinar :

Yahoo | November 2, 2023

Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer detection method at ESMO 2023¹, the annual congress of the European Society for Medical Oncology.

Yahoo | October 23, 2023

Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a clinical paper1 which shows that Volition's Nu.Q® NETs test is a promising biomarker for the evaluation of disease severity in septic shock patients and could play an important role in sepsis prognosis.

Yahoo | October 19, 2023

US Ambassador Adler visits Belgian Volition

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M. Adler, U.S. Ambassador to the Kingdom of Belgium for a tour of its purpose-built research, development and manufacturing facilities situated in Isnes, Belgium.

Yahoo | October 18, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!